Alterations in the excitability of dorsal root ganglion (DRG) neurons are critical in the pathogenesis of acute and chronic pain. Neurotransmitter release from the terminals of DRG neurons is regulated by cannabinoid receptor 1 (CB1) and transient receptor potential vanilloid 1 (TRPV1), both activated by anandamide (AEA). In our experiments, the AEA precursor N-arachidonoylphosphatidylethanolamine (20:4-NAPE) was used to study the modulation of nociceptive DRG neurons excitability using K+-evoked Ca2+ transients. Intrathecal administration was used to evaluate in vivo effects. Application of 20:4-NAPE at lower concentrations (10 nM - 1 µM) decreased the excitability of DRG neurons, whereas the higher (10 µM) increased it. Both effects of 20:4-NAPE were blocked by the N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) inhibitor LEI-401. Similarly, lower concentrations of externally applied AEA (1 nM - 10 nM) inhibited DRG neurons, whereas higher concentration (100 nM) did not change it. High AEA concentration (10 µM) evoked Ca2+ transients dependent on TRPV1 activation in separate experiments. Inhibition of the CB1 receptor by PF514273 (400 nM) prevented the 20:4-NAPE- and AEA-induced inhibition, whereas TRPV1 inhibition by SB366791 (1 µM) prevented the increased DRG neuron excitability. In behavioral tests, lower 20:4-NAPE concentration caused hyposensitivity, while higher evoked mechanical allodynia. Intrathecal LEI-401 prevented both in vivo effects of 20:4-NAPE. These results highlight anti- and pro-nociceptive effects of 20:4-NAPE mediated by CB1 and TRPV1 in concentration-dependent manner. Our study underscores the complexity of endocannabinoid signaling in pain transmission modulation and highlights 20:4-NAPE as a potential therapeutic target, offering new insights for developing analgesic strategies.

• Klíčová slova
• 20:4-NAPE, Anandamide, CB1, DRG neurons, NAPE-PLD, TRPV1,
• MeSH
• endokanabinoidy farmakologie   metabolismus   MeSH
• fosfatidylethanolaminy * farmakologie   MeSH
• fosfolipasa D * metabolismus   antagonisté a inhibitory   MeSH
• kationtové kanály TRPV metabolismus   MeSH
• krysa rodu Rattus MeSH
• kyseliny arachidonové * farmakologie   MeSH
• neurony * účinky léků   metabolismus   MeSH
• polynenasycené alkamidy farmakologie   MeSH
• potkani Sprague-Dawley MeSH
• receptor kanabinoidní CB1 metabolismus   MeSH
• spinální ganglia * účinky léků   metabolismus   cytologie   MeSH
• vápník metabolismus   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• anandamide MeSH Prohlížeč
• endokanabinoidy MeSH
• fosfatidylethanolaminy * MeSH
• fosfolipasa D * MeSH
• kationtové kanály TRPV MeSH
• kyseliny arachidonové * MeSH
• polynenasycené alkamidy MeSH
• receptor kanabinoidní CB1 MeSH
• Trpv1 protein, rat MeSH Prohlížeč
• vápník MeSH

Three decades ago, the first endocannabinoid, anandamide (AEA), was identified, and its analgesic effect was recognized in humans and preclinical models. However, clinical trial failures pointed out the complexity of the AEA-induced analgesia. The first synapses in the superficial laminae of the spinal cord dorsal horn represent an important modulatory site in nociceptive transmission and subsequent pain perception. The glutamatergic synaptic transmission at these synapses is strongly modulated by two primary AEA-activated receptors, cannabinoid receptor 1 (CB1) and transient receptor potential vanilloid 1 (TRPV1), both highly expressed on the presynaptic side formed by the endings of primary nociceptive neurons. Activation of these receptors can have predominantly inhibitory (CB1) and excitatory (TRPV1) effects that are further modulated under pathological conditions. In addition, dual AEA-mediated signaling and action may occur in primary sensory neurons and dorsal horn synapses. AEA application causes balanced inhibition and excitation of primary afferent synaptic input on superficial dorsal horn neurons in normal conditions, whereas peripheral inflammation promotes AEA-mediated inhibition. This review focuses mainly on the modulation of synaptic transmission at the spinal cord level and signaling in primary nociceptive neurons by AEA via CB1 and TRPV1 receptors. Furthermore, the spinal analgesic effect in preclinical studies and clinical aspects of AEA-mediated analgesia are considered.

• MeSH
• endokanabinoidy * metabolismus   MeSH
• kationtové kanály TRPV metabolismus   MeSH
• kyseliny arachidonové * metabolismus   farmakologie   MeSH
• lidé MeSH
• mícha * metabolismus   účinky léků   MeSH
• nervový přenos * fyziologie   účinky léků   MeSH
• nocicepce fyziologie   účinky léků   MeSH
• nociceptory metabolismus   účinky léků   fyziologie   MeSH
• polynenasycené alkamidy * metabolismus   MeSH
• receptor kanabinoidní CB1 metabolismus   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• anandamide MeSH Prohlížeč
• endokanabinoidy * MeSH
• kationtové kanály TRPV MeSH
• kyseliny arachidonové * MeSH
• polynenasycené alkamidy * MeSH
• receptor kanabinoidní CB1 MeSH